KLRK1 and hepatocellular carcinoma: In this study, blockade with anti-MCP1 and anti-IL-6 antibodies alone or in combination under hypoxia increased NK cell killing activity against HCC through the upregulation of NKG2D and NKp44, which are NK activation receptors (Figure 6).